N6-Benzyladenosine
Based on 1 Customer Validation
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma-.
For research use only. We do not sell to patients.
- Purity: 99.72%
- CAS No.: 4294-16-0
- Formula: C17H19N5O4
- Molecular Weight:357.36
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All Adenosine Receptor Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16 | IC50 |
>166.7 μM
Compound: BAPR
|
Antitumor activity against mouse B16 cells after 72 hrs by Calcein AM assay
Antitumor activity against mouse B16 cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| Caco-2 | GI50 |
7.4 μM
Compound: 19, BnA
|
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| CCRF-CEM | IC50 |
1.4 μM
Compound: BAPR
|
Antitumor activity against human CEM cells after 72 hrs by Calcein AM assay
Antitumor activity against human CEM cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| G-361 | IC50 |
>166.7 μM
Compound: BAPR
|
Antitumor activity against human G361 cells after 72 hrs by Calcein AM assay
Antitumor activity against human G361 cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| HL-60 | IC50 |
0.94 μM
Compound: BAPR
|
Antitumor activity against human HL60 cells after 72 hrs by Calcein AM assay
Antitumor activity against human HL60 cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| HOS | IC50 |
>166.7 μM
Compound: BAPR
|
Antitumor activity against human HOS cells after 72 hrs by Calcein AM assay
Antitumor activity against human HOS cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| HT-29 | GI50 |
22.3 μM
Compound: 19, BnA
|
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | GI50 |
2.92 μM
Compound: 19, BnA
|
Growth inhibition of 0.1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 72 hrs by MTS assay
Growth inhibition of 0.1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 72 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | GI50 |
2.92 μM
Compound: 19, BnA
|
Growth inhibition of 1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 72 hrs by MTS assay
Growth inhibition of 1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 72 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | GI50 |
3.91 μM
Compound: 19, BnA
|
Growth inhibition of 0.1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 48 hrs by MTS assay
Growth inhibition of 0.1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | GI50 |
4.17 μM
Compound: 19, BnA
|
Growth inhibition of 1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 48 hrs by MTS assay
Growth inhibition of 1 uM 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl) methyl] ester pretreated human K562 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | GI50 |
4.6 μM
Compound: 19, BnA
|
Antitumor activity against human K562 cells after 48 hrs by MTS assay
Antitumor activity against human K562 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | IC50 |
5.5 μM
Compound: BAPR
|
Antitumor activity against human K562 cells after 72 hrs by Calcein AM assay
Antitumor activity against human K562 cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| MCF7 | GI50 |
61 μM
Compound: 19, BnA
|
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| NIH3T3 | IC50 |
39 μM
Compound: BAPR
|
Cytotoxicity against mouse NIH 3T3 cells after 72 hrs by Calcein AM assay
Cytotoxicity against mouse NIH 3T3 cells after 72 hrs by Calcein AM assay
|
[PMID: 17418578] |
| Platelet | IC50 |
37.12 μM
Compound: 2d
|
Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry
Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry
|
[PMID: 25467153] |
| RD | CC50 |
4 μM
Compound: 23
|
Cytotoxicity against human RD cells
Cytotoxicity against human RD cells
|
[PMID: 26854380] |
| RD | EC50 |
0.28 μM
Compound: 23
|
Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay
Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay
|
[PMID: 26854380] |
N6-benzyladenosine suppresses the clonogenic activity and the growth of different neoplastic cells[2].
N6-benzyladenosine results cell morphology alteration and actin cytoskeleton disorganization in T24 cell[2].
N6-benzyladenosine (10 μM; 24 h) is a potent inductor of apoptosis, and belongs to apoptotic systems with distinct caspase-3 and caspase-9 activation[3].
N6-benzyladenosine (0-100 μM; 24 h) induces chromatin condensation, formation of apoptotic bodies, and cleavage of DNA to nucleosomal fragments in a dose-dependent manner[3].
N6-benzyladenosine acts as a selective anti-toxoplasma agent with binding affinity to T. gondii adenosine kinase (apparent Km =179.8 μM), over human adenosine kinase[4].
N6-benzyladenosine (0-50 μM) shows weak inhibition against adenosine kinase deficient (TgAKS3) strains of Toxoplasma gondii[4].
N6-benzyladenosine (compound 2) (0.3-20 μM) exerts anti-glioma activity by interfering with the mevalonate pathway and inhibiting FPPS (Farnesyl pyrophosphate synthase) [5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:Induced cell apoptosis by increasing caspase-3 (DEVDase) as well as caspase-9 (LEHDase) activity, indicating an apoptotic systems with distinct caspase-3/9 activation.
-
Cell Line:U87MG human glioma cell line.
-
Concentration:0.3, 0.6, 1.2, 2.5, 5, 10, 20 μM
-
Incubation Time:48 hours
-
Result:Inhibited glioma growth by interfering with the mevalonate pathway and inhibiting FPPS.
Chemical Information
-
CAS No. 4294-16-0
-
Appearance Solid
-
Molecular Weight 357.36
-
Formula C17H19N5O4
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O)[C@H](N2C(N=CN=C3NCC4=CC=CC=C4)=C3N=C2)O[C@@H]1CO
-
Synonyms
Benzyladenosine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 125 mg/mL (349.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[2]. Castiglioni S, et al. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anticancer Agents Med Chem. 2013 May;13(4):672-8. [Content Brief]
[3]. Mlejnek P. Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem. 2001;83(4):678-89. [Content Brief]
[4]. Kim YA, et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem Pharmacol. 2007 May 15;73(10):1558-72. [Content Brief]
[5]. Grimaldi M, et al. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. Bioorg Chem. 2020 May;98:103449. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7983 mL | 13.9915 mL | 27.9830 mL | 69.9575 mL |
| 5 mM | 0.5597 mL | 2.7983 mL | 5.5966 mL | 13.9915 mL | |
| 10 mM | 0.2798 mL | 1.3991 mL | 2.7983 mL | 6.9957 mL | |
| 15 mM | 0.1866 mL | 0.9328 mL | 1.8655 mL | 4.6638 mL | |
| 20 mM | 0.1399 mL | 0.6996 mL | 1.3991 mL | 3.4979 mL | |
| 25 mM | 0.1119 mL | 0.5597 mL | 1.1193 mL | 2.7983 mL | |
| 30 mM | 0.0933 mL | 0.4664 mL | 0.9328 mL | 2.3319 mL | |
| 40 mM | 0.0700 mL | 0.3498 mL | 0.6996 mL | 1.7489 mL | |
| 50 mM | 0.0560 mL | 0.2798 mL | 0.5597 mL | 1.3991 mL | |
| 60 mM | 0.0466 mL | 0.2332 mL | 0.4664 mL | 1.1660 mL | |
| 80 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8745 mL | |
| 100 mM | 0.0280 mL | 0.1399 mL | 0.2798 mL | 0.6996 mL |